Search
Lexicon Pharmaceuticals Inc
LXRXAdd to Watchlist
2.310USD
-0.030-1.28%
Close 07-31 16:00（ET）Quotes delayed by 15 min
1.03BMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-31The current earnings forecast score of Lexicon Pharmaceuticals Inc is 7.60, ranking 281 out of 385 in the Biotechnology & Medical Research industry. The average price target is 1.90, with a high of 6.00 and a low of 1.00.
Analyst Rating
Based on
5
analysts
Buy
Current Rating
3.770
Target Price
+63.20%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
Lexicon Pharmaceuticals Inc
LXRX
5
Beigene Ltd
ONC
28
Ionis Pharmaceuticals Inc
IONS
27
argenx SE
ARGX
26
Kymera Therapeutics Inc
KYMR
24
Insmed Inc
INSM
23
1
2
3
...
99
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Lexicon Pharmaceuticals Inc's expected revenue for the next quarter?
Lexicon Pharmaceuticals Inc's expected revenue is 4.00M.
What is Lexicon Pharmaceuticals Inc's price target?
Analysts forecast that Lexicon Pharmaceuticals Inc's price target is USD 1.90, with the highest forecast at USD 6.00 and the lowest forecast at USD 1.00.
How have Lexicon Pharmaceuticals IncLXRX's recent earnings per share performed?
The market expectation was USD -0.00, while Lexicon Pharmaceuticals IncLXRX's earnings per share (EPS) for the previous quarter was USD -0.04. EPS for the next quarter is expected at USD -0.05.
What is the analyst rating for Lexicon Pharmaceuticals Inc?
Based on the ratings of Lexicon Pharmaceuticals Inc's stock from 5 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.